Notables from Sinovac's (SVA) financial results: 1) stripping out 2011 Panflu sales related to...

|About: Sinovac Biotech, Ltd. (SVA)|By:, SA News Editor

Notables from Sinovac's (SVA) financial results: 1) stripping out 2011 Panflu sales related to the government's stockpiling program, Q4 and FY12 sales rose 166.9% and 38.6% respectively; 2) success in Phase III clinicals for EV71 vaccine made 2012 a "transformative year" for the company; 3) growth in sales of core products (Healive, Bilive, Anflu) "very" pleasing. SVA also says Mexican regulators have approved the commercialization of the seasonal flu vaccine. Shares +1.2% premarket.